Wolfe Research Initiates Coverage On Kestra Medical Techs with Outperform Rating, Announces Price Target of $29
Author: Benzinga Newsdesk | March 31, 2025 09:07am
Wolfe Research analyst Mike Polark initiates coverage on Kestra Medical Techs (NASDAQ:KMTS) with a Outperform rating and announces Price Target of $29.